189 related articles for article (PubMed ID: 35246970)
1. A novel signature based on immune-related gene pairs and clinical features to predict prognosis and treatment effect in "driver gene negative" lung adenocarcinoma.
Cai HY; Yang HS; Shan SC; Lei YY; Zou JY; Zhu Y; Luo HH
Cancer Med; 2022 Jun; 11(11):2259-2270. PubMed ID: 35246970
[TBL] [Abstract][Full Text] [Related]
2. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
3. A radiomics nomogram prediction for survival of patients with "driver gene-negative" lung adenocarcinomas (LUAD).
Guo QK; Yang HS; Shan SC; Chang DD; Qiu LJ; Luo HH; Li HP; Ke ZF; Zhu Y
Radiol Med; 2023 Jun; 128(6):714-725. PubMed ID: 37219740
[TBL] [Abstract][Full Text] [Related]
4. Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.
Chen M; Wang X; Wang W; Gui X; Li Z
Front Immunol; 2022; 13():829057. PubMed ID: 35833114
[TBL] [Abstract][Full Text] [Related]
5. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
Wu C; Rao X; Lin W
Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
[TBL] [Abstract][Full Text] [Related]
6. Construction and Validation of a Novel Immune-Related Gene Pairs-Based Prognostic Model in Lung Adenocarcinoma.
Liu Y; Zhou J; Wu J; Zhang X; Guo J; Xing Y; Xie J; Bai Y; Hu D
Cancer Control; 2023; 30():10732748221150227. PubMed ID: 36625357
[TBL] [Abstract][Full Text] [Related]
7. Methylation of N6 adenosine-related long noncoding RNA: effects on prognosis and treatment in 'driver-gene-negative' lung adenocarcinoma.
Yang HS; Cai HY; Shan SC; Chen TF; Zou JY; Abudurufu M; Luo HH; Lei YY; Ke ZF; Zhu Y
Mol Oncol; 2023 Feb; 17(2):365-377. PubMed ID: 36221911
[TBL] [Abstract][Full Text] [Related]
8. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
Chen G; Dong Z; Wu D; Chen Y
J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
10. The construction and analysis of ceRNA network and patterns of immune infiltration in lung adenocarcinoma.
Li J; Liu W; Dong X; Dai Y; Chen S; Zhao E; Liu Y; Bao H
BMC Cancer; 2021 Nov; 21(1):1228. PubMed ID: 34781924
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-related gene signature for predicting LUAD patients' prognosis and immune microenvironment.
Chen J; Fu Y; Hu J; He J
Cytokine; 2022 Apr; 152():155820. PubMed ID: 35176657
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
13. Abnormal Expression and Prognostic Significance of Bone Morphogenetic Proteins and Their Receptors in Lung Adenocarcinoma.
Xu Z; Chen C
Biomed Res Int; 2021; 2021():6663990. PubMed ID: 34036102
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.
Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J
Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302
[TBL] [Abstract][Full Text] [Related]
15. Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma.
Cao K; Liu M; Ma K; Jiang X; Ma J; Zhu J
Cancer Immunol Immunother; 2022 Jun; 71(6):1295-1311. PubMed ID: 34652523
[TBL] [Abstract][Full Text] [Related]
16. A promising prognostic signature for lung adenocarcinoma (LUAD) patients basing on 6 hypoxia-related genes.
Luo J; Du X
Medicine (Baltimore); 2021 Dec; 100(50):e28237. PubMed ID: 34918689
[TBL] [Abstract][Full Text] [Related]
17. Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma.
Yu Q; Zhao L; Yan XX; Li Y; Chen XY; Hu XH; Bu Q; Lv XP
World J Surg Oncol; 2022 Jun; 20(1):183. PubMed ID: 35668494
[TBL] [Abstract][Full Text] [Related]
18. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Wang J; Zhan X
Front Immunol; 2021; 12():752643. PubMed ID: 34887858
[TBL] [Abstract][Full Text] [Related]
19. Development of the prognostic value in lung adenocarcinoma based on anoikis-related genes and initial experimental validation.
Guo W; Zhao G; Liu S; Deng T; Zhang G; Zhang B
J Gene Med; 2023 Sep; 25(9):e3534. PubMed ID: 37259225
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis reveals the potential value of inflammatory response genes in the prognosis, immunity, and drug sensitivity of lung adenocarcinoma.
Song C; Pan S; Li D; Hao B; Lu Z; Lai K; Li N; Geng Q
BMC Med Genomics; 2022 Sep; 15(1):198. PubMed ID: 36117156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
